Ming-Ling Chang1,2, Chia-Jung Kuo1, Li-Heng Pao3,4, Chen-Ming Hsu1, Cheng-Tang Chiu1. 1. a Liver Research Center, Division of Hepatology, Department of Gastroenterology and Hepatology , Chang Gung Memorial Hospital , Taoyuan, Taiwan. 2. b Department of Medicine , College of Medicine, Chang Gung University , Taoyuan, Taiwan. 3. c Graduate Institute of Health-Industry Technology, Chang Gung University of Science and Technology , Taoyuan, Taiwan. 4. d Research Center for Industry of Human Ecology, Chang Gung University of Science and Technology , Taoyuan, Taiwan.
Abstract
BACKGROUND: The evolution of the relationship between adiponectin and insulin sensitivity in hepatitis C virus (HCV) patients during viral clearance is unclear and warrants investigation. METHODS: A prospective study including 747 consecutive chronic hepatitis C (CHC) patients, of whom 546 had completed a course of anti-HCV therapy and underwent pre-, peri- and post-therapy surveys for anthropomorphic, viral, metabolic and hepatic profiles and adiponectin levels, was conducted in a tertiary care center. RESULTS: Multivariate analyses indicated associations of sex, triglyceride levels and hepatic steatosis with adiponectin levels and of triglyceride levels and interferon λ3 (IFNL3) genotype with homeostasis model assessment-estimated insulin resistance (HOMA-IR) levels before anti-HCV therapy. In patients with a sustained virological response (SVR; n = 455), at 24 weeks post-therapy, sex, BMI, aspartate aminotransferase to platelet ratio index (APRI), HOMA-IR and steatosis were associated with adiponectin levels, and IFNL3 genotype was associated with HOMA-IR levels. GEE analysis demonstrated that SVR affected longitudinal trends in adiponectin levels. Compared with pre-therapy levels, adiponectin and APRI levels decreased 24 weeks post-therapy in SVR patients, regardless of baseline insulin resistance (IR). However, HOMA-IR levels decreased in SVR patients with baseline IR but increased in those without baseline IR. Compared with controls, immunohistochemical studies showed that pre-therapy CHC patients had higher hepatic adiponectin expression associated with hepatic fibrosis. CONCLUSIONS: During HCV infection, adiponectin may affect insulin sensitivity through triglycerides. After viral clearance, adiponectin levels were directly associated with insulin sensitivity and decreased upon improved hepatic fibrosis; with a link to the IFNL3 genotype, insulin sensitivity improved only in patients with baseline IR.
BACKGROUND: The evolution of the relationship between adiponectin and insulin sensitivity in hepatitis C virus (HCV) patients during viral clearance is unclear and warrants investigation. METHODS: A prospective study including 747 consecutive chronic hepatitis C (CHC) patients, of whom 546 had completed a course of anti-HCV therapy and underwent pre-, peri- and post-therapy surveys for anthropomorphic, viral, metabolic and hepatic profiles and adiponectin levels, was conducted in a tertiary care center. RESULTS: Multivariate analyses indicated associations of sex, triglyceride levels and hepatic steatosis with adiponectin levels and of triglyceride levels and interferon λ3 (IFNL3) genotype with homeostasis model assessment-estimated insulin resistance (HOMA-IR) levels before anti-HCV therapy. In patients with a sustained virological response (SVR; n = 455), at 24 weeks post-therapy, sex, BMI, aspartate aminotransferase to platelet ratio index (APRI), HOMA-IR and steatosis were associated with adiponectin levels, and IFNL3 genotype was associated with HOMA-IR levels. GEE analysis demonstrated that SVR affected longitudinal trends in adiponectin levels. Compared with pre-therapy levels, adiponectin and APRI levels decreased 24 weeks post-therapy in SVR patients, regardless of baseline insulin resistance (IR). However, HOMA-IR levels decreased in SVR patients with baseline IR but increased in those without baseline IR. Compared with controls, immunohistochemical studies showed that pre-therapy CHCpatients had higher hepatic adiponectin expression associated with hepatic fibrosis. CONCLUSIONS: During HCV infection, adiponectin may affect insulin sensitivity through triglycerides. After viral clearance, adiponectin levels were directly associated with insulin sensitivity and decreased upon improved hepatic fibrosis; with a link to the IFNL3 genotype, insulin sensitivity improved only in patients with baseline IR.
Authors: Ian Homer Y Cua; Jason M Hui; Priyanka Bandara; James G Kench; Geoffrey C Farrell; Geoffrey W McCaughan; Jacob George Journal: Hepatology Date: 2007-07 Impact factor: 17.425
Authors: M Derbala; N Rizk; S Al-Kaabi; A Amer; F Shebl; A Al Marri; I Aigha; D Alyaesi; H Mohamed; H Aman; N Basem Journal: J Viral Hepat Date: 2009-03-25 Impact factor: 3.728
Authors: Teegan R Lim; Jonathan M Hazlehurst; Andrei I Oprescu; Matthew J Armstrong; Sewa F Abdullah; Nigel P Davies; Robert Flintham; Peter Balfe; David J Mutimer; Jane A McKeating; Jeremy W Tomlinson Journal: Clin Endocrinol (Oxf) Date: 2019-01-17 Impact factor: 3.478